Pharmaceutical Mail. The Committee for Medicinal Products for Human Use of the European Medicines Agency, EMA, has issued a positive opinion recommending the authorization of Benepali, the biosimilar version of Samsung Bioepis from Enbrel (etanercept), from Amgen and Pfizer, for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
